Chong, A.; Min, L.; Gunalan, K.; Raman, R.; Renia, L.; Nosten, F.; Shochat, S. G.; Dao, M.; Sasisekharan, R.; Suresh, S.; Preiser, P. Citation Chandramohanadas, R., Basappa , Russell, B., Liew, K., Yau, Y. H., Chong, A., Min, L., Gunalan, K., Raman, R., Renia, L., Nosten, F., Shochat, S. G., Dao, M., Sasisekharan, R., Suresh, S., & Preiser, P. (2014 by guest on
Introduction
Malaria remains a major health concern for the developing world. Although recent trends suggest a progressive decline, nearly 220 million malaria infections (causing ~700,000 deaths) occurred in 2010 alone [1] . These data largely focus on Plasmodium (P.) falciparum infections in Africa and gravely underestimate the contribution of Plasmodium vivax, which may account for another 200 million infections in Asia and South America. Thus, malaria against which vaccine development efforts are still ongoing [2] , exerts an enormous burden on global human health [3] . Efforts to treat malaria largely rely on chemotherapeutic approaches to block parasitic replication besides preventive measures targeting the mosquito vector. However, recent emergence of resistance against chloroquine [4] and reduced efficacy of artemisinin [5] point to the critical need for exploring new set of antimalarial targets.
Merozoite entry into erythrocytes is driven by complex recognition events between parasitic proteins and sugar moieties on the host red blood cells (RBCs) [6, 7] . Merozoites bind to sialic acid residues on RBC receptors for invasion [8] , however, sialic acid-independent invasion pathways have also been elucidated [9, 10] . While several plasmodial proteins play critical roles during invasion, Merozoite Surface Proteins (MSPs) and Apical Membrane Antigens (AMAs) have been the most studied. Among MSPs, MSP-1 is considered a prime candidate for vaccine development [11, 12] . It is required for the attachment of merozoites to host receptors such as Band 3 [13] and for normal parasitic development [14] . MSP-1 undergoes two proteolytic processing steps during merozoite maturation [15] . Following cleavage, MSP-1 complex remains non-covalently attached to the merozoite surface until invasion, except for a small fragment of 19-kDa from the C-terminus (MSP-1 19 ) that remains attached to the merozoite even after invasion. Antibodies targeting MSP-1 19 epitopes [16, 17] block merozoite invasion, illustrating a definite invasionassociated role of this domain. In addition, MSP-1 19 is involved in normal parasitic development [17] and food vacuole formation [18] .
Glycan derivatives interfere with replication and invasion of P. falciparum [19] [20] [21] . Especially, sulfated glycosaminoglycans are known to block merozoite A c c e p t e d M a n u s c r i p t 4 [22] and sporozoite invasion [23] . It has been shown that heparin blocks merozoite invasion by binding to a specific domain of MSP-1 termed MSP-1 33 thereby preventing the secondary proteolytic processing [24] . Although MSP-1 19 does not bind to heparin-like glycosaminoglycan oligosaccharides [24] , its ability to bind to small molecules has not been investigated. In this study, we report the identification of a small molecule, 2-butyl-5-chloro-3-(4-nitro-benzyl)-3H-imidazole-4-carbaldehyde (NIC) capable of binding to MSP-1 19 of human malaria parasites: P. falciparum and P. vivax. Using different approaches, we demonstrate that NIC interacts with EGF-like domains present on MSP-1 19 .
These observations collectively point to the possibility of targeting plasmodial invasion proteins for antimalarial drug development.
Materials and Methods

Parasites and reagents
Collection of blood for Plasmodium culture was verified and approved by the Institutional Review Board (IRB) of National University of Singapore (NUS). P. falciparum strain, 3D7 was used for all experiments unless otherwise stated. shapes. Ligand poses at these sites were selected based on shape matching, using a cutoff distance of 3 Å. Structure based high-throughput virtual screening method of LigandFit (DS version 2.5) was used to identify potential ligands that interact with MSP-1 (PDB ID: X) using NCBI database [44] . Glycan-mimetic small molecules such as KI-105, DMBO, BIC, NIC, CIC, and DIC were synthesized as reported [45] . These compounds were purified and characterized using Agilent 1200 series LC system (Agilent ZORBAX, Eclipse-XDB-C18, 5 μm, 4.6 mm x 150 mm).
Docking of small molecule ligands to MSP-1 19
All ligands were subjected to LigandFit docking to determine reasonable conformations for each low energy conformer at the binding site. ovale were performed using 'build homology modeling' protocol by DS version 2.5.
SPR measurements
SPR measurements were conducted using a Biacore™ T-200 instrument (Biacore, GE Healthcare). MSP-1 19 peptide was directly immobilized onto a flow cell on a CM5-S sensor chip (Biacore, GE Healthcare) through standard amine Giemsa-stained smears using microscopy.
Results
Identification of NIC as a potential ligand against EGF-like domains of Plasmodial MSP-1
Antibodies targeting EGF-like domains on the C-terminal motif (MSP-119) prevent host invasion. We therefore, set out to identify small molecules that can bind to MSP-1 19 domain as invasion blockers. First, using the X-ray crystal structure of P. falciparum Based on these computational analyses, we posited that NIC could bind with a higher affinity to EGF-like domains present on MSP-1 19 compared to other structurally related compounds (Table. 1 A c c e p t e d M a n u s c r i p t Leu32, Asn33, Tyr34, Lys35 and Gln36. NIC was likely to form additional bonds with Glu51, Asn52, Asn53, Gly54 and Gly55 (Fig. 1C) . Also, it appears that NIC has the unique ability to bind to MSP-1 19 through its ionic nitro-group on the benzene ring making it the most suitable ligand. Sequence alignment of residues within the EGF-like domains of MSP-1 19 from multiple plasmodia revealed remarkable conservation of key residues that are positioned to make contact with NIC (Fig. 1D) . Many of these conserved residues were within epitopes recognized by invasion-blocking antibodies against MSP-1. (Fig. 2A) . Notably, BCI, which served as the negative control as well as heparin, showed no measurable interaction with MSP-1 19 as expected from previous reports [24] .
NIC specifically interacts with
We determined the affinity constant from a fit to a simple binding isotherm in an equilibrium analysis, with an estimated value in the tens of micromolar range (~ 37 µM) (Fig. 2B) . Since we could not reach saturation of the surface due to lack of solubility of NIC at high concentrations (under conditions used for SPR measurements), and thus the calculated value of Rmax could not be precise, we chose to show the range for the value of affinity constant by To validate the interaction of NIC with its parasitic target, we first conducted colocalization experiments using NIC-biotin (Supplemental Fig. S1B, S1C ) that has comparable invasion inhibitory effects on malaria parasites as NIC (Supplemental Fig. S1D ). Using a parasite line that expresses MSP-1 19 -GFP, A c c e p t e d M a n u s c r i p t we observed co-localization of NIC-biotin with MSP-1 in late-stage schizonts (Fig. 2C) . In contrast, ring or trophozoite stage parasites when very little MSP-1 is present showed no detectable labeling with NIC-biotin (Supplemental Fig.   S1E ). However, due to the dispersed nature of GFP distribution in these parasites [30], it was not possible to conclusively document co-localization.
Hence, fluorescence microscopy was repeated using antibodies against MSP-1 19 together with NIC-biotin (Supplemental Fig. S1 F) ; further supporting an interaction between NIC and MSP-1 19 .
Next, we used NIC-biotin to identify parasitic targets. Schizont-stage parasites were fractionated into infected red cell/ extra-parasitic (iRBC) and parasitic fractions by differential extraction using saponin [31] . Further, each sample was incubated with 50 M NIC-biotin and then with streptavidin-agarose beads to affinity purify proteins that interact with NIC. Aliquots from un-bound and bound fractions from each sample were resolved on SDS-PAGE and polypeptides visualized by Coomassie staining. Enrichment of a low molecular weight protein (Fig. 2D) was observed from the parasitic fraction and was identified as MSP- (Fig. 3A) with a median IC50 of 18 M. Potential non-specific interaction of NIC with red cell proteins was ruled out by pre-incubating RBCs with NIC for 2 h and washing them prior to mixing with late-stage parasites. RBCs that were pre-treated with NIC supported normal parasite invasion and growth (Fig. 3B) . Microscopic evaluation of Giemsastained smears revealed that NIC treatment resulted in impaired merozoite invasion. Clumps of agglutinated merozoites were observed in smears prepared from post-rupture time points (Fig. 3C) after NIC treatment. NIC showed comparable inhibitory potential on a number of plasmodial strains tested (Table. 2) demonstrating a conserved target.
Further, ring stage parasites (~12 hpi) were treated with 20μM NIC and phenotypes monitored at specific intervals (15, 30, 45 and 60 hpi) using Giemsa-stained smears. By 60 hpi, all the schizonts had ruptured and established rings in the control (DMSO) vials while merozoites failed to invade in presence of NIC (Fig. 3D) . The invasion inhibition by NIC was confirmed by live video microscopy [32] . In presence of NIC, the schizonts appeared to burst slowly and despite making initial contact with RBCs, merozoites failed to invade even after several minutes (Supplemental Videos; S2A and S2B). Next, invasion inhibition assays were conducted by mixing purified merozoites [33] with fresh RBCs in presence of NIC. This experiment revealed a strong and specific invasion inhibition in presence of NIC (Fig. 3E) . Negative control (BCI) showed no significant inhibitory effects on invasion even at 200μM. Although there are minor differences in the sensitivity to the inhibitors of purified merozoites compared to intact schizonts, these experiments provide strong evidence for the invasion inhibitory activity of NIC. Furthermore, schizont-stage parasites (~ 45 hpi) were exposed for 2 h to NIC and NIC was removed by washing. These parasites were able to invade efficiently, revealing NIC's specific inhibitory effect solely on invasion (Supplemental Fig. S1H) .
A c c e p t e d M a n u s c r i p t (Fig. 3F) compared to PfM3', in agreement with the computational predictions. BCI-treated parasites (PfM3'
and PcMEGF) served as controls and showed no apparent differences in sensitivity (Fig. 3G) . These data functionally validate the interaction between NIC and MSP-1 19 , leading to impairment of invasion.
NIC inhibits P. vivax invasion
The residues within EGF-like domains of MSP- (Fig. 4A) , however with lower affinity compared to PfMSP-1 19 (Fig. 4B) . The effect of NIC on ex vivo invasion of P. vivax into human reticulocytes was tested using a recently developed assay [36] . Purified schizonts from clinical isolates were mixed with enriched reticulocytes in presence of different amounts of NIC. BCI-treated parasites served as negative control while an anti-Duffy antibody (2C3) that blocks invasion at 25 g/ml concentration served as positive control. After 24 hours, newly invaded reticulocytes were counted by a field-based flow cytometry assay [37] (Fig. 4C) .
A concentration-dependent inhibition of invasion by NIC on P. vivax merozoites was observed with an average IC 50 of 23.6 M. BCI showed no inhibition even at 100 M concentration. These results were further verified by microscopic inspection of Giemsa-stained blood smears (Fig. 4D) . In BCI-treated samples, robust invasion was observed (Fig. 4D-Upper M a n u s c r i p t Globin A c c e p t e d M a n u s c r i p t 
